论文部分内容阅读
近十年一些研究显示：特异性抗原、抗体结合形成的免疫复合物ＩＣ，经经典途径激活补体，并由人或灵长类动物红血球 （Ｒｅｄ ｂｌｏｏｄ ｃｅｌｌｓ，Ｒｂｃ；Ｅｒｙｔｈｒｏｃｙｃｅ，Ｅ）上存在的Ｃ３ｂ受体ＣＲ１介导，先与循环中Ｒｂｃ结合，后由其携带，再经过肝、脾中的网状内皮等系统处理，而得以清除。本文报道，用先生物素化的抗－ＣＲＩ和抗－人ＩｓＭ（抗原）的两种单抗，后以链球亲合素（Ｓｔｒｅｐｔａｖｉｄｉｎ，ＳＡ）交联成的异源多聚体（Ｈｅｔｅｒｏｐｏｌｙｍｅｒ，ＨＰ）分别灌注到５只不同的在循环中预先注射了１２５Ｉ标记的血源性“病原体模式”抗原（人ＩｇＭ）的栗鼠猴体内，结果发现都促进了抗原（Ａg）与Ｒｂｃ的结合，其被清除的量约达７０％～９０％。同时，在每个Ｒｂｃ上ＣＲ1数目有一定的降低，它类似于被Ｃ３ｂ调理的ⅠC在通常被清除时ＣＲ１降低的一般观察结果；吸收Ｈｐ－ＡgⅠＣ的主要器官是肝和脾。这方面工作的最终目的是将可利用不同ＨＰ系统在体内清除Ａｇ，使其成为临床上对疾病的一种潜在性免疫学治疗手段。
In the last decade, some studies have shown that specific antigens, antibodies bind to the immune complex IC formed, activate complement by the classical pathway and are expressed by C3b present on human or primate red blood cells (Rbc; Erythrocyce, E) Receptor CR1 mediated, first with the cycle of Rbc binding, after its carrying, and then through the liver, spleen and other reticuloendothelial system and other treatment, and be cleared. We report here that heterologous multimers (Heteropolymer, HP) crosslinked with streptavidin (SA) using two monoclonal antibodies to the anti-CRI and anti-human IsM (antigens) ) Were individually perfused into 5 different chinchilla monkeys pre-injected with125I-labeled blood-borne “pathogen-mode” antigen (human IgM) in the circulation and were found to promote the binding of antigen (Ag) to Rbc Clear amount of about 70% to 90%. At the same time, there was a certain decrease in the number of CR1 at each Rbc, which is similar to the general observation that CR decreased when CIc-conditioned ICCs were normally cleared; the main organs that absorb Hp-AgIC are liver and spleen. The ultimate goal of this work is to remove Ag from the body using different HP systems, making it a potentially immunotherapeutic approach to disease in the clinic.